IL6 and plasma cell myeloma: However, in patients with relapsed-refractory multiple myeloma (RRMM), there was no benefit to the addition of siltuximab, an IL-6 inhibitor, to bortezomib and/or dexamethasone-containing treatment regimes in non-transplant settings (55, 56).